JAMA Editors' Summary Platelet Transfusion in Preterm Infants, Pediatric Solid Organ Transplants, Measles Case Tracking, and more
21 snips
Sep 19, 2025 Delve into groundbreaking neonatal platelet transfusion algorithms that could change preterm care. Discover insights from the T‑Mate pediatric heart transplant trial and the complexities of measles case tracking. The discussion also touches on donor-derived EBV risks in kidney transplants. Engaging viewpoints tackle the intersection of research investment and women’s health, plus emerging applications of GLP‑1 treatment. A lively chat about AI safety rounds out the conversation, making this a must-listen for those interested in pediatric medicine.
AI Snips
Chapters
Transcript
Episode notes
Personalized Platelet Transfusion Decisions
- The prediction model assesses benefit vs harm of prophylactic platelet transfusion in preterm infants with severe thrombocytopenia.
- Benefit varies with platelet count and clinical context, supporting individualized decisions.
Threshold Curve Over Fixed Cutoff
- The study supports a threshold curve where benefits of transfusion are outweighed by risks above certain platelet counts.
- This framing moves beyond a single numeric cutoff toward risk–benefit curves for decisions.
Everolimus Regimen Shows Comparable Outcomes
- The T-Mate trial found no difference in prevention of rejection or vasculopathy between everolimus+low tacrolimus and standard regimens.
- Everolimus appeared safe and may improve kidney function and reduce infections.